A detailed history of Alpha Core Capital LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Alpha Core Capital LLC holds 9,456 shares of GILD stock, worth $875,341. This represents 0.18% of its overall portfolio holdings.

Number of Shares
9,456
Previous 10,075 6.14%
Holding current value
$875,341
Previous $691,000 14.62%
% of portfolio
0.18%
Previous 0.17%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$66.59 - $83.99 $41,219 - $51,989
-619 Reduced 6.14%
9,456 $792,000
Q2 2024

Aug 12, 2024

BUY
$63.15 - $72.88 $14,145 - $16,325
224 Added 2.27%
10,075 $691,000
Q1 2024

May 15, 2024

SELL
$71.58 - $87.29 $26,341 - $32,122
-368 Reduced 3.6%
9,851 $721,000
Q4 2023

Feb 13, 2024

SELL
$73.27 - $83.09 $9,158 - $10,386
-125 Reduced 1.21%
10,219 $827,000
Q3 2023

Nov 13, 2023

BUY
$73.94 - $80.67 $36,970 - $40,335
500 Added 5.08%
10,344 $775,000
Q2 2023

Aug 09, 2023

BUY
$76.01 - $86.7 $52,826 - $60,256
695 Added 7.6%
9,844 $758,000
Q1 2023

May 11, 2023

BUY
$77.31 - $88.08 $23,193 - $26,424
300 Added 3.39%
9,149 $759,000
Q4 2022

Feb 14, 2023

SELL
$62.32 - $89.47 $9,971 - $14,315
-160 Reduced 1.78%
8,849 $759,000
Q3 2022

Nov 09, 2022

BUY
$59.54 - $68.01 $109,851 - $125,478
1,845 Added 25.75%
9,009 $556,000
Q2 2022

Aug 12, 2022

BUY
$57.72 - $65.01 $89,292 - $100,570
1,547 Added 27.54%
7,164 $443,000
Q1 2022

May 04, 2022

BUY
$57.92 - $72.58 $325,336 - $407,681
5,617 New
5,617 $334,000
Q2 2020

Aug 14, 2020

SELL
$72.34 - $84.0 $75,884 - $88,116
-1,049 Closed
0 $0
Q1 2020

May 04, 2020

BUY
$62.63 - $80.22 $65,698 - $84,150
1,049 New
1,049 $78,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $116B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Alpha Core Capital LLC Portfolio

Follow Alpha Core Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Core Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Core Capital LLC with notifications on news.